Navigation Links
Henry Ford West Bloomfield Hospital Launches Gene Therapy Study for Parkinson's Disease
Date:10/6/2009

WEST BLOOMFIELD, Mich., Oct. 6 /PRNewswire/ -- Henry Ford West Bloomfield Hospital is embarking on a research study for advanced Parkinson's disease using a state-of-the-art treatment called gene transfer.

The clinical trial will test whether gene transfer therapy is able to restore better mobility in Parkinson's patients who have lost responsiveness to drug therapy.

"The start of this clinical trial provides hope to a Parkinson's disease patient population that has had a long-standing need for better treatment options," says Henry Ford West Bloomfield Hospital neurologist Peter LeWitt, M.D.

Parkinson's disease is a degenerative disorder of the central nervous system that causes tremors and impairs a person's motor skills, speech, balance and posture. Its cause is unknown and it affects 1 percent to 2 percent of people over the age of 60.

Of the eight sites in the United States involved in the study, Henry Ford West Bloomfield Hospital is the only Michigan institution testing this experimental therapy.

A small region deep within the brain is the source for the symptoms of Parkinson's disease. When brain neurons in this part of the brain begin to die, these cells can no longer manufacture the molecule dopamine, a chemical critical for controlling movement.

Among patients with Parkinson's disease, the pace and extent of progression in neurologic deficits can greatly vary. The burden on quality of life spans a wide spectrum too, Dr. LeWitt says, from minimal discomfort and disability to marked impairment of capabilities such as independence, safety and communication.

Most current therapies and research approaches target dopamine to treat motor symptoms associated with Parkinson's disease. In contrast, the focus of the current gene therapy strategy is on increasing GABA, a brain neurotransmitter that regulates movement. In Parkinson's disease, GABA is reduced in an area of the brain called the subthalamic nucleus, causing it to be overactive. Investigators feel this might be a better way to help advanced Parkinson's disease.

For the clinical trial, the gene therapy product rAAV-GAD will be placed into the subthalamic nucleus by a surgical procedure. The gene transfer is done through a catheter that is removed shortly after its placement. Participants will be assessed post-treatment at multiple intervals. As an alternative to this experimental treatment, patients with advanced Parkinson's disease have the option of deep brain stimulation. This also involves a surgical procedure in which a pacemaker-like device is placed in the brain to help in control of Parkinson's disease symptoms.

LeWitt notes that the Henry Ford Parkinson's Disease and Movement Disorders Program is devoted to bringing the most promising therapies. This program is also working with experimental approaches for slowing progression of Parkinson's disease.

To learn more about the study, call 248-355-2452.

About Henry Ford Parkinson's Disease and Movement Disorders Program

The Henry Ford Parkinson's Disease and Movement Disorders Program is a Center of Excellence based in Southfield and at other Henry Ford locations. It provides treatment and research for Parkinson's disease, tremors, and other movement disorders. The Henry Ford program provides routine diagnostic services and treatment for Parkinson's disease, as well as several investigational studies for new treatments. Research carried out is searching for better treatments and possible ways to arrest the progression of Parkinson's disease, including neuroprotection strategies and an upcoming gene therapy clinical trial.

SOURCE Henry Ford Health System


'/>"/>
SOURCE Henry Ford Health System
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Henry Ford Macomb Hospital Deploys PerfectServe at Warren Campus to Improve Communication, Better Coordinate Care
2. Henry Ford Hospital Offers Free Prostate Cancer Screenings
3. Apollo PACS, Inc. Selected by Henry Ford Health System for Its Digital Pathology Solution
4. Henry Schein to Present at the Morgan Stanley Global Healthcare Unplugged Conference
5. 12th Annual Henry Schein Back-to-School Events Help 2,000 Underserved Children Return to the Classroom in Style
6. Henry M. Jackson Foundation names fellowship award winners
7. Atlanta Sleep Medicine Clinic Views Representative Henry Waxman's Denial of Restless Leg Syndrome as a Sign of General Lack of Awareness of the Sleep Disorder
8. CSC Signs $115 Million IT Services Renewal Agreement With Henry Ford Health System
9. Oklahoma Passes Comprehensive Tort Reform: Governor Brad Henry Signs Reform Legislation
10. Henry Ford Hospital: Unique Patient Study -- No Informed Consent
11. Doctors at Henry Ford Health System Treat Ovarian, Prostate, Lung, and Other Forms of Cancer Using Novalis Tx(TM) Platform for Image-Guided Radiosurgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2017)... ... April 24, 2017 , ... Pitavastatin, a relatively ... it is not known to have significant interactions with antiretroviral therapy (ART). ... cholesterol levels and dampen inflammation in the bloodstream. , While lowering cholesterol and ...
(Date:4/24/2017)... ... 24, 2017 , ... Labs often perform the same operations ... operators and management to assess these processes with a critical eye—particularly in the ... , Created with the help of both internal and external process experts, ...
(Date:4/24/2017)... ... ... “Reflections of God’s Work”: an enlightening collection of life lessons leading each person ... author, Jerri Broglin, a survivor of great loss who gained insight on how to ... those searching for answers, as we are finding the answers that are so deep ...
(Date:4/24/2017)... ... April 24, 2017 , ... ... PA will be attending the 2017 Oral Reconstruction Foundation’s 2017 Symposium on Tissue ... Oral Reconstruction Foundation will present its annual Global Symposium at the Fontainebleau Hotel ...
(Date:4/24/2017)... ... 24, 2017 , ... Anaconda BioMed, a pre-clinical stage medical ... treatment of Acute Ischemic Stroke (AIS), today announced it has appointed Creganna Medical ... towards regulatory and clinical phases. , "This is another important step for Anaconda ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... R.I. , April 20, 2017  CVS ... CVS), today unveiled a new store design to ... assortment of healthier food, health-focused products and expanded ... store to help customers discover new offerings. Together ... the next evolution of the customer experience at ...
(Date:4/20/2017)... , April 20, 2017  AbbVie (NYSE: ABBV), ... percent (n=145/146) of chronic hepatitis C virus (HCV) ... or 6 and compensated cirrhosis (Child-Pugh A) achieved ... 12 ) with its investigational, pan-genotypic regimen of ... were seen following 12 weeks of G/P treatment ...
(Date:4/20/2017)... Eyevensys, a private biotechnology company ... expression technology that enables the safe, local, sustained production ... wide range of ophthalmic diseases, announces it has received ... Agency (MHRA) to advance its technology into clinical development. ... The EyeCET ...
Breaking Medicine Technology: